Objective Although rare, renal amyloidosis is an important diagnosis that bares a significant morbidity and mortality. The purpose of this study was to present current single center experience in the past 28 years. Methods A total of 6151 kidney biopsies were performed in our hospital from Jan. 1983 to Dec. 2010; 5844 were native kidney biopsies. Cases with a diagnosis of renal amyloidosis were identified through a search of our data bank and the clinical data were retrieved from medical charts. The patients were further classified as AL type and non-AL type. The trend of incidence was analyzed and the clinical features were compared. Risk factors that predict patient mortality were discovered by logistic regression analysis. Results Forty out of 5844 native kidney biopsies (0.68%) were identified as renal amyloidosis. Eighteen (45%) were of AL type. The mean age at diagnosis was 62.6 ± 13.4 years. Male was the predominant gender that was involved. Clinically, most (80%) have nephrotic range proteinuria (mean 24 hours urine protein: 6.9 ± 4.7 g). With a mean follow-up duration of 1155 day, the 1-year and 5-year patient survival were 42.9% and 17.9%, respectively. eGFR at biopsy was the sole predictive factor for patient survival. Conclusion Senile patients with nephrotic syndrome should elicit the suspicion of renal amyloidosis. The incidence appeared to be increasing and the prognosis poor.
Introduction
The kidney is a major organ that is most frequently involved in systemic amyloidosis. Previous research revealed a poor prognosis in such patients (1) . The urgent problem is the increasing incidence of this disease (2) . Whether this increase is a worldwide trend has not been established. We have previously reported the clinicopathological spectrum of renal amyloidosis in a small series in Taiwan (3) . With the addition of more cases during an extended period, we are able to better delineate the trend and clinical picture of renal amyloidosis. This report was aimed at exploring the clinical features and long-term outcome in our hospital over the past 28 years.
Materials and Methods

Patients
From January 1983 to December 2010, 6,151 kidney biopsies were performed in our hospital. There were 307 cases of kidney allograft biopsies while the remaining 5,844 were native kidney biopsies. Renal amyloidosis was identified in 40 cases. The following clinical data were retrieved from charts and retrospectively analyzed: age, gender, duration between apparent onset and biopsy, 24 hours urine protein, hematuria (per high power field), hematocrit, serum albumin, serum total protein, estimated glomerular filtrate rate (eGFR calculated by MDRD equation), total cholesterol, tri- glyceride, lactate dehydrogenase (LDH), immunoglobin A (IgA), immunoglobin G (IgG), immunoglobin M (IgM), immunoglobin E (IgE), systolic blood pressure (SBP), diastolic blood pressure (DBP), kidney size, sodium (Na + ), potassium (K + ), calcium (Ca 2+ ), and number of involved organs. Patients with a discharge diagnosis of amyloidosis regardless of type of organs involved were also identified through a search in the database of our hospital.
Diagnosis of renal amyloidosis
Biopsy samples were embedded in paraffin, sectioned at 3 μm and stained with Hematoxylin-Eosin, periodic acid Schiff, periodic acid silver methenamine and Masson trichrome. Congo red staining was performed when the diagnosis of amyloidosis was suspected, either pathologically or clinically. Specimens for immunofluoresence study were snap-frozen, sectioned at 5 μm and stained with antibodies against the following items: C1q, fibrinogen, kappa and lambda light chain. Ultrathin sectioning (60 nm) for electron microscopy was routinely performed when tissue samples were available. A typical apple green birefringence found under polarized microscope established the diagnosis of amyloidosis. When possible, this was further confirmed under electron microscopic examination when typical fibril was documented (4) . The diagnosis of AL type was based on the discovery of clinical proteinuria, positive amyloid staining by Congo red in renal biopsy, evidence that the amyloid is light chain-related established by direct examination of the amyloid, monoclonal plasma cell proliferative disorder (M protein in urine or serum, free light chain ratio abnormality, or clonal plasma cells in the bone marrow biopsy) (5). The immunohistochemistry for amyloid A protein was unavailable in our hospital, therefore, non AL types are all the other types, except for the ones mentioned above.
Heart involvement
Heart involvement of amyloidosis was defined as the findings from electrical cardiogram (ECG) of low voltage in the limb leads or poor R wave progression in the precordial leads, or an echocardiographic finding of impaired relaxation pattern with reversal of E/A ratio (6) . Cardiac biopsy was used in a few cases as a diagnostic tool.
Statistical analysis
Data were expressed as means and standard deviations or percentage. Comparison between groups was carried out by using Mann-Whitney U test (for continuous variables) or Chi-Square test (for categorical variables). The changing pattern of incidence across the 28 years was analyzed by simple linear regression model to give the trend. A specific analysis of the trend was performed on the incidences obtained after years 1995 when the National Health Insurance (NHI) program was launched. Because this program covers almost the whole population in Taiwan, the incidence obtained during this period might more appropriately reflect reality. Clinical parameters among the 5 chronic kidney disease (CKD) stages were compared by using Kruskal Wallis test. A Kaplan-Meier plot for survival analysis was performed and further compared with Log rank test if necessary. Logistic regression analysis was used to identify risk factors for patients' one-year survival. A p value <0.05 was considered as statistically significant. All analyses were performed with SPSS version 12.0 statistic software.
Results
Forty cases of renal amyloidosis were diagnosed histologically which represented 0.68% of all native renal biopsies or 2.22% of patients with proteinuria (1794 cases). They comprised 18 AL and 22 non-AL cases. A computerbased search revealed 84 patients with a discharge diagnosis of amyloidosis no matter what organs were involved. We also collected all amyloidosis patients in the past 28 years and there were 84 patients with amyloidosis (not only limited to kidney). The kidney was the most common site of involvement (47.6%, 40/84) followed by bone marrow (25%, 21/84).
The incidence over the past 28 years is shown in (Fig. 1 ). Setting a cut-off point at the year 1995, a steady increase of incidence was found (y=0.01144x-0.0033, R 2 =0.8619, p= 0.023) since year 1995. A similar trend was also discovered for AL amyloidosis (y=0.0118x-0.0174, R 2 =0.8585, p= 0.024) but not for non-AL type (y=-0.0005x+0.0142, R 2 = 0.0909, p=0.318) (Fig. 2 ). An increasing trend was also found in females (y=0.0094x-0.0132, R 2 =0.8688, p=0.033) but not in males (Fig. 3) .
Patient characteristics were compared between AL and non-AL amyloidosis cases (Table 1) . Males were predominant in both groups. The mean age at diagnosis was 62.6, with 85% cases over 50 years as a whole. Proteinuria was well above the nephrotic range (6.9 ± 4.7 g/day) and only 20% had proteinuria of between 1-3.5 g/day. None had a proteinuria <1 g/day. Mean systolic and diastolic blood pressure were at lower normal limits (117.3 mmHg and 73.4 mmHg, respectively). As a whole, there were only 4 cases (10%) of hypertension (systolic blood pressure >140 mmHg) while 42.5% patients had a systolic BP <110 mmHg. There was no enlargement of kidney size. The number of organs involved was 2.69 ± 0.91.
To compare disease severity, patients were further stratified according to the stages of chronic kidney disease (CKD). Stage 3 CKD was distinguished as being the most severe stage in terms of proteinuria, which is shown by the lowest serum albumin, calcium and sodium level. These parameters tended to normalize eventually even as the disease progressed.
After renal biopsy, most patients died within one year and the median survival was 234 days (0.64 years) (Fig. 4) . The mean follow-up duration was 1155 days (3.16 years) (median: 240 days (0.65 years)). Patients with heart involvement had a worse prognosis although it was not statistically significant (p=0.085) (Fig. 5) . Logistic regression analysis revealed that eGFR was the only factor that predicted patient survival ( Table 2 ).
Discussion
The incidence of renal amyloidosis varies from 0.85% to 4.8% (7-11) in different countries. The incidence was lower in the present study, 0.68% of the total native kidney biopsies or 2.2% for those with proteinuria. However, great caution should be taken in the interpretation of the low incidence. As mentioned previously, the National Health Insurance program was launched in 1995 which covered the vast majority of people and offer co-payments as low as US $5 per office visit. Under these circumstances, people had free access to medical facilities with little financial burden. For this reason, we consider our data of incidence after 1995 as a better assessment in reflecting reality. Thus, the incidence was 2.57% during this period, which was close to that reported in other countries. Moreover, the incidence appeared to be increasing during this period (Fig. 1) (p=0.023) . This finding is consistent with that of Nishi et al (2) in which the majority of cases were diagnosed during the recent 20 years. The underlying mechanism of the trend is obscure, but may be partly due to the aging of the general population which results in more aged people who are at high risk of developing amyloidosis. After 1995, the mean age of diagnosis per Furthermore, the types matter in the above-mention trend. Only AL amyloidosis displayed a similar trend with statistical significance (p=0.024) (Fig. 2) . We hypothesized that aging might still be an important contributing factor to the increasing incidence in AL amyloidosis. Most non-AL amyloidosis cases are due to chronic inflammation, which is not age-dependent. Some of the chronic inflammatory disease cases are infection related, and may actually decrease as the economics improve. For instance, chronic tuberculosis was once widespread in Taiwan. With the improvement in health care, it is not until recent decades that it was no longer endemic. Indeed, disease prevalence in countries with different economic background manifest differently. AL is more prevalent in developed countries whereas AA is more prevalent in developing countries (12) (13) (14) . Our finding also suggested that the increasing incidence of AL type may reflect a better recognition of this disease in recent years. As far as gender is concerned, females (p=0.033) denoted a similar trend when compared with males (Fig. 3) although the total number of males exceeded that of females (Table 1) . Key issues regarding whether females are becoming more susceptible to the development of AL amyloidosis in recent years remains uncertain. This finding is new to the current literature and needs further investigation.
There was a long duration between apparent onset of disease and biopsy (Table 1) . One possible cause for this delay is the culture element, which is that people generally lack the willingness to receive an invasive procedure. Even so, the postponed management was not correlated with a poor prognosis in logistic regression for survival (Table 2) . It is reasonable to speculate that the lack of effective treatment even with earlier diagnosis may account for this phenomenon.
The present patients had a marked proteinuria (6.9 ± 4.7 g, Table 1 ) and 80% had nephrotic range proteinuria. This finding is consistent with previous reports (15) . The patients also had a certain degree of renal function impairment (mean eGFR: 56.5 ± 28 mL/min, Table 1 ) and 40% of patients had an eGFR of less than 50 mL/min. In contrast, a high incidence (42.5%) of low systolic BP (defined as <110 mmHg) was found. Furthermore, there were only 4 cases (10%) of hypertension (defined as >140 mmHg). This striking feature is in line with prior studies (9) , in which cardiac involvement and autonomous neuropathy were implicated as the cause of normotension (16) (17) (18) .
Although amyloidosis is a disease of profuse fibril deposition, our study indicated no enlargement of kidney size (Table 1) . Inconsistent data on renal size in amyloidosis were reported (10, 19, 20) . We found that the kidney size did not vary significantly among different stages of CKD (data not shown). Our data suggests that amyloid deposition might actually prevent atrophy of kidneys as can be expected in most end-stage renal diseases.
Different types of amyloidosis may affect the kidney dif- ferently. In previous studies, glomerulus was found to be the main site of amyloid deposition in AL (21-23), whereas non-AL type mainly involved vessels and renal tubules (24) . Under this circumstance, one may predict a higher degree of proteinuria in AL type. However, we found no statistically significant differences in the severity of proteinuria between these 2 groups. However, the serum albumin was significantly lower in non-AL type (Table 1) . With a similar degree of proteinuria, the low serum albumin might reflect the state of chronic inflammation that was associated with non-AL amyloidosis. Interestingly, our data showed that serum albumin was the lowest in patients with stage 3 CKD and it rose gradually as the disease progressed although not statistically significant (p=0.073). It was accompanied with a similar change in serum sodium (p=0.008) and calcium (not different significantly). For advanced stages of CKD, we expected that the magnitude of proteinuria might decrease as more nephron mass is destroyed by the amyloid fibril. Thus, nephrotic syndrome may not be function as a sole indicator in assessing disease severity even though it is a cardinal feature.
The median survival of 234 days in the present study was inferior to the study of Kyle and Gertz (22 months) (1) . Of the 40 patients, 14 patients had expired at the end of followup. There were 8 deaths of heart disease (3 due to heart failure and 5 due to arrhythmia) and 6 deaths of infection (5 due to pneumonia, and one due to peritonitis). On logistic regression analysis, eGFR is the sole predictor for patients' mortality (Table 2 ). However, we did observe a trend toward significance in heart involvement (Fig. 5) . Prior studies have shown that elevated serum creatinine, heart involvement, and interstitial fibrosis are risk factors of mortality (1) . The small case numbers in our series may have rendered the statistics underpowered to detect the significance of other possible risk factors such as cardiac involvement.
The present study has several limitations that warrant further study. First, immunohistochemistry study for AA type amyloid was not performed which prevented further classification for non-AL patients. Due to equipment and financial limitation and medical policy, the hospital was not provided amyloid A stain. Therefore, we classified renal amyloidosis into AL type and non-AL type. Not performing IHC stain might increase the chance of incorrect typing. However, we were unable to re-stain all 40 samples because our hospital only preserves each sample for 10 years, which lead to much selection bias. Secondly, the total case number in this study was too low to draw a firm conclusion. Third, a detailed pathological analysis was not performed; hence the correlation between the pathological changes and clinical features was unknown. Lastly, many patients were lost to follow-up before they developed end-stage renal failure due to the retrospective study design, the details of the subsequent development were not available. Thus, the survival analysis may be affected.
Conclusion
In conclusion, renal amyloidosis is a disease of poor prognosis and increasing incidence, especially in females and AL amyloidosis. The presence of nephrotic syndrome in elderly patients with a relatively low blood pressure should prompt the suspicion of renal amyloidosis.
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